Reducing blood side effects in cervical cancer treatment
Part of Blood & lymphatic, Cancer, Women’s health & pregnancy clinical trials.
This study tests whether a different way of giving standard chemoradiation can lower the risk of blood-related side effects (like low blood cell counts) in people with locally advanced cervical cancer, while still controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older (patients over 70 need a short geriatric health questionnaire).
- You have cervical cancer (squamous cell, adenocarcinoma, or adenosquamous) that is locally advanced (stage IB3 to IVA) and can be treated with curative intent.
- Cancer has not spread outside the pelvic/para-aortic area (confirmed by imaging and/or laparoscopy).
- Your blood counts and organ function are adequate (e.g., hemoglobin ≥ 9 g/dL, platelets ≥ 100,000/mm³).
- You are healthy enough to receive cisplatin- or carboplatin-based chemotherapy.
- You are not pregnant, not breastfeeding, and if you could become pregnant, you use highly effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a radiation plan that is adjusted day by day to better match your cervix and surrounding tissues during treatment. It’s for newly diagnosed, advanced cervical cancer patients who will receive standard pelvic radiation and chemotherapy.
This trial tests a type of radiation that adapts to your body changes during treatment for cervical cancer. It aims to improve accuracy and reduce side effects.
This study looks at blood markers—tiny DNA from the blood (cfDNA) and minimal residual disease (MRD)—to better predict outcomes after standard chemoradiotherapy for locally advanced cervical cancer. It may help doctors identify who is more likely to do well and who may need closer follow-up or additional treatment planning.
This trial tests whether giving radiation to a smaller area of the pelvis is enough to treat stage IIb cervical cancer, while sparing more healthy tissue. It may help reduce side effects and improve your quality of life during and after treatment.
This trial tests a shorter course of radiation combined with chemotherapy and brachytherapy (internal radiation) for cervical cancer that has not spread widely. It aims to make treatment more efficient while still being effective.
This trial tests a feasibility (“can it be done safely?”) approach that delivers radiation in a shorter schedule for some cervical cancer patients. It also uses weekly cisplatin chemotherapy and includes a radiation procedure called brachytherapy to improve treatment effectiveness.
Hear when a new Cervical Cancer by FIGO Stage 2018 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.